The combination of a KDM5A inhibitor and deacetylase inhibitor has been hypothesized to be effective at both inhibiting cell proliferation by counteracting the overexpression of EMSY/KDM5A/SIN3B and, at the same time, preventing cancer cell resistance to drugs [71, 92]. The gene discussed is KDM5A; the disease is cancer.